Loading data for NVO — first visit, this takes a few seconds.

Novo Nordisk A/S

NYSE: NVO · Real-Time Price · USD
46.60
-0.91 (-1.92%)
At close: Sep 04, 2026, 3:59 PM
46.55
-0.11%
After-hours: 7:59 PM

The price, the headline numbers and the latest news, in one place.

Novo Nordisk A/S (NVO) Stock Price, Analysis & Data

-1.92% (1D)
Bid46.5
Market Cap206B
Revenue (ttm)329B
Net Income (ttm)116B
0.34
4.07
11.45
13.63
P/B (ttm)6.02
P/S (ttm)0.63
Earnings DateNov 4, 2026
Ask46.66
Volume6,119,184
Avg. Volume (20D)11,980,534
Open46.35
Previous Close47.51
Day's Range46.04 - 46.74
52-Week Range35.12 - 64.16
Analystn/a
Price Targetn/a
Dividends$1.80 (3.78%)
Ex-Dividend DateAug 17, 2026

About NVO

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine...

Sector Healthcare
IPO Date Apr 30, 1981
Employees 66,700
Stock Exchange NYSE
Ticker Symbol NVO
Full Company Profile

Financial Performance

In 2025, Novo Nordisk A/S's revenue was 309.06B, an increase of 6.43% compared to the previous year's 290.4B. Earnings were 102.43B, an increase of 1.43%.

Financial Statements

Earnings Surprise

Novo Nordisk A/S has released their quarterly earnings on Aug 4, 2026:
  • Revenue of $78.49B misses estimates by $0, with 2.12% YoY growth.
  • EPS of 6.18 exceeds estimates by 1.20, with 3.69% YoY growth.
Novo Nordisk A/S is scheduled to release its earnings on Nov 4, 2026, before market opens.
Analysts project revenue of ... Upgrade